Fortress Biotech, Inc.
FBIO
$2.31
$0.093.83%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.05% | -5.13% | -10.21% | -13.50% | -12.80% |
| Total Other Revenue | 102.30% | -84.16% | -87.52% | -94.86% | -94.88% |
| Total Revenue | 9.69% | -23.56% | -28.23% | -32.11% | -31.76% |
| Cost of Revenue | -57.79% | -46.68% | -45.49% | -51.11% | -39.69% |
| Gross Profit | 251.40% | 886.00% | 192.33% | 107.38% | 54.78% |
| SG&A Expenses | 10.21% | 41.02% | 47.45% | 18.53% | -0.25% |
| Depreciation & Amortization | 24.39% | -32.78% | -27.27% | -19.80% | -9.13% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.64% | -7.42% | -6.63% | -24.51% | -25.53% |
| Operating Income | 33.96% | -8.76% | -12.77% | 18.82% | 21.66% |
| Income Before Tax | 72.02% | 56.55% | 16.90% | 22.83% | 21.60% |
| Income Tax Expenses | -295.06% | -19.20% | -22.12% | -22.12% | -22.12% |
| Earnings from Continuing Operations | 72.77% | 56.42% | 16.92% | 22.83% | 21.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -46.93% | -22.92% | 11.60% | -21.74% | -19.95% |
| Net Income | 114.82% | 108.22% | 63.80% | 24.49% | 24.14% |
| EBIT | 33.96% | -8.76% | -12.77% | 18.82% | 21.66% |
| EBITDA | 35.64% | -9.15% | -13.86% | 18.99% | 21.48% |
| EPS Basic | 98.17% | 93.86% | 70.25% | 64.92% | 68.11% |
| Normalized Basic EPS | 160.14% | -50.12% | 148.38% | 162.41% | 148.55% |
| EPS Diluted | 95.71% | 91.86% | 69.02% | 64.89% | 68.09% |
| Normalized Diluted EPS | 105.16% | -56.90% | 145.52% | 162.41% | 148.55% |
| Average Basic Shares Outstanding | 36.68% | 61.70% | 84.37% | 111.50% | 150.40% |
| Average Diluted Shares Outstanding | 47.52% | 75.05% | 89.85% | 111.50% | 150.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | 1.00% | 1.00% | 0.67% | 0.34% |